"","Phase","Status","URL Name","URL","Disease ID","Disease Name","Drug ID","Drug Name","Mechanism of Action","Action Type","Target ID","Target Approved Name","Target Approved Symbol","Drug Type","NCT_ID"
"1",4,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05732064","MONDO_0007254","breast cancer","CHEMBL395091","ESKETAMINE","Glutamate [NMDA] receptor negative allosteric modulator","NEGATIVE ALLOSTERIC MODULATOR","ENSG00000176884","glutamate ionotropic receptor NMDA type subunit 2A","GRIN2A","Small molecule","NCT05732064"
"2",4,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00172029","MONDO_0007254","breast cancer","CHEMBL924","ZOLEDRONIC ACID","Farnesyl diphosphate synthase inhibitor","INHIBITOR","ENSG00000160752","farnesyl diphosphate synthase","FDPS","Small molecule","NCT00172029"
"3",4,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03355157","MONDO_0007254","breast cancer","CHEMBL553025","VINORELBINE","Tubulin inhibitor","INHIBITOR","ENSG00000188229","tubulin beta 3 class III","TUBB3","Small molecule","NCT03355157"
"4",4,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04248179","EFO_0000432","breast ductal carcinoma in situ","CHEMBL1077896","ROPIVACAINE","Sodium channel alpha subunit blocker","BLOCKER","ENSG00000144285","sodium voltage-gated channel alpha subunit 4","SCN4A","Small molecule","NCT04248179"
"5",4,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02864030","MONDO_0007254","breast cancer","CHEMBL1683544","ERIBULIN MESYLATE","Tubulin inhibitor","INHIBITOR","ENSG00000188229","tubulin beta 6 class V","TUBB6","Small molecule","NCT02864030"
"6",4,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05072314","MONDO_0007254","breast cancer","CHEMBL79","LIDOCAINE","Sodium channel alpha subunit blocker","BLOCKER","ENSG00000144285","sodium voltage-gated channel alpha subunit 2","SCN2A","Small molecule","NCT05072314"
"7",4,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02447328","MONDO_0007254","breast cancer","CHEMBL1358","FULVESTRANT","Estrogen receptor antagonist","ANTAGONIST","ENSG00000140009","estrogen receptor 1","ESR1","Small molecule","NCT02447328"
"8",4,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04136782","MONDO_0007254","breast cancer","CHEMBL3545252","DOCETAXEL","Tubulin inhibitor","INHIBITOR","ENSG00000188229","tubulin beta 4A class IVa","TUBB4A","Small molecule","NCT04136782"
"9",4,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05840068","MONDO_0007254","breast cancer","CHEMBL1431","METFORMIN","Mitochondrial complex I (NADH dehydrogenase) inhibitor","INHIBITOR","ENSG00000198695","NADH:ubiquinone oxidoreductase subunit S6","NDUFS6","Small molecule","NCT05840068"
"10",4,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04248179","EFO_0000432","breast ductal carcinoma in situ","CHEMBL658","SUFENTANIL","Mu opioid receptor agonist","AGONIST","ENSG00000112038","opioid receptor mu 1","OPRM1","Small molecule","NCT04248179"
"11",4,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02005770","MONDO_0004379","female breast carcinoma","CHEMBL1200694","SEVOFLURANE","GABA-A receptor; anion channel positive allosteric modulator","OPENER","ENSG00000169427","gamma-aminobutyric acid type A receptor subunit alpha6","GABRA6","Small molecule","NCT02005770"
"12",4,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00082277","MONDO_0007254","breast cancer","CHEMBL1654","RISEDRONATE SODIUM","Farnesyl diphosphate synthase inhibitor","INHIBITOR","ENSG00000160752","farnesyl diphosphate synthase","FDPS","Small molecule","NCT00082277"
"13",4,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01094184","MONDO_0007254","breast cancer","CHEMBL428647","PACLITAXEL","Tubulin inhibitor","INHIBITOR","ENSG00000188229","tubulin beta 2A class IIa","TUBB2A","Small molecule","NCT01094184"
"14",4,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01743560","MONDO_0007254","breast cancer","CHEMBL1908360","EVEROLIMUS","FK506-binding protein 1A inhibitor","INHIBITOR","ENSG00000088832","FKBP prolyl isomerase 1A","FKBP1A","Small molecule","NCT01743560"
"15",4,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03355157","MONDO_0007254","breast cancer","CHEMBL189963","PALBOCICLIB","Cyclin-dependent kinase 4/cyclin D1 inhibitor","INHIBITOR","ENSG00000110092","cyclin dependent kinase 4","CDK4","Small molecule","NCT03355157"
"16",4,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05362760","MONDO_0007254","breast cancer","CHEMBL3301610","ABEMACICLIB","Cyclin-dependent kinase 6 inhibitor","INHIBITOR","ENSG00000105810","cyclin dependent kinase 6","CDK6","Small molecule","NCT05362760"
"17",4,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03360214","MONDO_0007254","breast cancer","CHEMBL1889140","ROPIVACAINE HYDROCHLORIDE","Sodium channel alpha subunit blocker","BLOCKER","ENSG00000144285","sodium voltage-gated channel alpha subunit 11","SCN11A","Small molecule","NCT03360214"
"18",4,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05033769","MONDO_0007254","breast cancer","CHEMBL1683590","ERIBULIN","Tubulin inhibitor","INHIBITOR","ENSG00000188229","tubulin beta 8 class VIII","TUBB8","Small molecule","NCT05033769"
"19",4,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02005770","MONDO_0004379","female breast carcinoma","CHEMBL526","PROPOFOL","GABA-A receptor; anion channel positive allosteric modulator","POSITIVE ALLOSTERIC MODULATOR","ENSG00000022355","gamma-aminobutyric acid type A receptor subunit gamma3","GABRG3","Small molecule","NCT02005770"
"20",4,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02344940","MONDO_0007254","breast cancer","CHEMBL1655","TOREMIFENE","Estrogen receptor modulator","MODULATOR","ENSG00000140009","estrogen receptor 1","ESR1","Small molecule","NCT02344940"
"21",4,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02248571","EFO_0000305","breast carcinoma","CHEMBL1773","CAPECITABINE","Thymidylate synthase inhibitor","INHIBITOR","ENSG00000176890","thymidylate synthetase","TYMS","Small molecule","NCT02248571"
"22",4,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05631795","MONDO_0007254","breast cancer","CHEMBL2396661","ALPELISIB","PI3-kinase p110-alpha subunit inhibitor","INHIBITOR","ENSG00000121879","phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha","PIK3CA","Small molecule","NCT05631795"
"23",4,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00688909","MONDO_0007254","breast cancer","CHEMBL1444","LETROZOLE","Cytochrome P450 19A1 inhibitor","INHIBITOR","ENSG00000137869","cytochrome P450 family 19 subfamily A member 1","CYP19A1","Small molecule","NCT00688909"
"24",4,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01298193","MONDO_0007254","breast cancer","CHEMBL1471","APREPITANT","Neurokinin 1 receptor antagonist","ANTAGONIST","ENSG00000115353","tachykinin receptor 1","TACR1","Small molecule","NCT01298193"
"25",4,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01553903","MONDO_0007254","breast cancer","CHEMBL1399","ANASTROZOLE","Cytochrome P450 19A1 inhibitor","INHIBITOR","ENSG00000137869","cytochrome P450 family 19 subfamily A member 1","CYP19A1","Small molecule","NCT01553903"
"26",4,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03355157","MONDO_0007254","breast cancer","CHEMBL1200374","EXEMESTANE","Cytochrome P450 19A1 inhibitor","INHIBITOR","ENSG00000137869","cytochrome P450 family 19 subfamily A member 1","CYP19A1","Small molecule","NCT03355157"
"27",4,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00372476","MONDO_0007254","breast cancer","CHEMBL941","IMATINIB","Stem cell growth factor receptor inhibitor","INHIBITOR","ENSG00000097007","KIT proto-oncogene, receptor tyrosine kinase","KIT","Small molecule","NCT00372476"
"28",4,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00082277","MONDO_0007254","breast cancer","CHEMBL923","RISEDRONIC ACID","Farnesyl diphosphate synthase inhibitor","INHIBITOR","ENSG00000160752","farnesyl diphosphate synthase","FDPS","Small molecule","NCT00082277"
"29",4,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00537771","MONDO_0007254","breast cancer","CHEMBL786","TAMOXIFEN CITRATE","Estrogen receptor alpha modulator","MODULATOR","ENSG00000091831","estrogen receptor 1","ESR1","Small molecule","NCT00537771"
"30",4,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03123770","MONDO_0007254","breast cancer","CHEMBL53463","DOXORUBICIN","DNA topoisomerase II alpha inhibitor","INHIBITOR","ENSG00000131747","DNA topoisomerase II alpha","TOP2A","Small molecule","NCT03123770"
"31",4,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03360214","MONDO_0007254","breast cancer","CHEMBL1098","BUPIVACAINE","Sodium channel protein type IV alpha subunit blocker","BLOCKER","ENSG00000007314","sodium voltage-gated channel alpha subunit 4","SCN4A","Small molecule","NCT03360214"
"32",4,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03360214","MONDO_0007254","breast cancer","CHEMBL1200396","BUPIVACAINE HYDROCHLORIDE","Sodium channel protein type IV alpha subunit blocker","BLOCKER","ENSG00000007314","sodium voltage-gated channel alpha subunit 4","SCN4A","Small molecule","NCT03360214"
"33",4,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05161195","MONDO_0007254","breast cancer","CHEMBL3545110","RIBOCICLIB","Cyclin-dependent kinase 6 inhibitor","INHIBITOR","ENSG00000135446","cyclin dependent kinase 6","CDK6","Small molecule","NCT05161195"
"34",4,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01907880","MONDO_0007254","breast cancer","CHEMBL834","PAMIDRONIC ACID","Farnesyl diphosphate synthase inhibitor","INHIBITOR","ENSG00000160752","farnesyl diphosphate synthase","FDPS","Small molecule","NCT01907880"
"35",4,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05732064","MONDO_0007254","breast cancer","CHEMBL778","DEXMEDETOMIDINE","Adrenergic receptor alpha-2 agonist","AGONIST","ENSG00000150594","adrenoceptor alpha 2A","ADRA2A","Small molecule","NCT05732064"
"36",4,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01553903","MONDO_0007254","breast cancer","CHEMBL83","TAMOXIFEN","Estrogen receptor alpha modulator","MODULATOR","ENSG00000091831","estrogen receptor 1","ESR1","Small molecule","NCT01553903"
"37",4,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05807074","MONDO_0007254","breast cancer","CHEMBL877","TRANEXAMIC ACID","Plasminogen inhibitor","INHIBITOR","ENSG00000122194","plasminogen","PLG","Small molecule","NCT05807074"
"38",3,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02115282","EFO_0000304","breast adenocarcinoma","CHEMBL27759","ENTINOSTAT","Histone deacetylase inhibitor","INHIBITOR","ENSG00000116478","histone deacetylase 6","HDAC6","Small molecule","NCT02115282"
"39",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01234337","MONDO_0007254","breast cancer","CHEMBL1336","SORAFENIB","Tyrosine-protein kinase receptor RET inhibitor","INHIBITOR","ENSG00000165731","ret proto-oncogene","RET","Small molecule","NCT01234337"
"40",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01091168","MONDO_0007254","breast cancer","CHEMBL2110725","VINFLUNINE","Tubulin inhibitor","INHIBITOR","ENSG00000188229","tubulin alpha 3c","TUBA3C","Small molecule","NCT01091168"
"41",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01101438","MONDO_0007254","breast cancer","CHEMBL1703","METFORMIN HYDROCHLORIDE","Mitochondrial complex I (NADH dehydrogenase) inhibitor","INHIBITOR","ENSG00000198695","mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1","MT-ND1","Small molecule","NCT01101438"
"42",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00081796","MONDO_0007254","breast cancer","CHEMBL4279455","LAROTAXEL","Tubulin stabiliser","STABILISER","ENSG00000188229","tubulin beta 1 class VI","TUBB1","Small molecule","NCT00081796"
"43",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01610284","MONDO_0007254","breast cancer","CHEMBL2017974","BUPARLISIB","PI3-kinase class I inhibitor","INHIBITOR","ENSG00000145675","phosphoinositide-3-kinase regulatory subunit 2","PIK3R2","Small molecule","NCT01610284"
"44",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00080301","MONDO_0007254","breast cancer","CHEMBL1201752","IXABEPILONE","Tubulin inhibitor","INHIBITOR","ENSG00000188229","tubulin beta 4A class IVa","TUBB4A","Small molecule","NCT00080301"
"45",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00390455","EFO_1000294","HER2 Positive Breast Carcinoma","CHEMBL1201179","LAPATINIB DITOSYLATE","Epidermal growth factor receptor erbB1 inhibitor","INHIBITOR","ENSG00000146648","epidermal growth factor receptor","EGFR","Small molecule","NCT00390455"
"46",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03337724","MONDO_0007254","breast cancer","CHEMBL2177390","IPATASERTIB","Serine/threonine-protein kinase AKT inhibitor","INHIBITOR","ENSG00000105221","AKT serine/threonine kinase 1","AKT1","Small molecule","NCT03337724"
"47",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01645839","MONDO_0007254","breast cancer","CHEMBL803","CYTARABINE","DNA polymerase (alpha/delta/epsilon) inhibitor","INHIBITOR","ENSG00000101868","DNA polymerase alpha 2, accessory subunit","POLA2","Small molecule","NCT01645839"
"48",3,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04639986","MONDO_0007254","breast cancer","CHEMBL538943","VINORELBINE TARTRATE","Tubulin inhibitor","INHIBITOR","ENSG00000188229","tubulin beta 8 class VIII","TUBB8","Small molecule","NCT04639986"
"49",3,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04799249","EFO_0005537","triple-negative breast cancer","CHEMBL3894860","TRILACICLIB","Cyclin-dependent kinase 4 inhibitor","INHIBITOR","ENSG00000135446","cyclin dependent kinase 4","CDK4","Small molecule","NCT04799249"
"50",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00078572","MONDO_0007254","breast cancer","CHEMBL554","LAPATINIB","Receptor protein-tyrosine kinase erbB-2 inhibitor","INHIBITOR","ENSG00000146648","erb-b2 receptor tyrosine kinase 2","ERBB2","Small molecule","NCT00078572"
"51",3,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05760378","EFO_0005537","triple-negative breast cancer","CHEMBL1278146","FAMITINIB","Platelet-derived growth factor receptor inhibitor","INHIBITOR","ENSG00000122025","platelet derived growth factor receptor alpha","PDGFRA","Small molecule","NCT05760378"
"52",3,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05382286","MONDO_0007254","breast cancer","CHEMBL888","GEMCITABINE","DNA polymerase (alpha/delta/epsilon) inhibitor","INHIBITOR","ENSG00000167325","DNA polymerase delta 3, accessory subunit","POLD3","Small molecule","NCT05382286"
"53",3,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05501886","MONDO_0007254","breast cancer","CHEMBL592445","GEDATOLISIB","PI3-kinase class I inhibitor","INHIBITOR","ENSG00000145675","phosphoinositide-3-kinase regulatory subunit 3","PIK3R3","Small molecule","NCT05501886"
"54",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00006459","MONDO_0007254","breast cancer","CHEMBL1637","GEMCITABINE HYDROCHLORIDE","DNA polymerase (alpha/delta/epsilon) inhibitor","INHIBITOR","ENSG00000167325","DNA polymerase alpha 2, accessory subunit","POLA2","Small molecule","NCT00006459"
"55",3,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05306340","MONDO_0007254","breast cancer","CHEMBL384467","DEXAMETHASONE","Glucocorticoid receptor agonist","AGONIST","ENSG00000113580","nuclear receptor subfamily 3 group C member 1","NR3C1","Small molecule","NCT05306340"
"56",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04874935","MONDO_0007254","breast cancer","CHEMBL480","LANSOPRAZOLE","Potassium-transporting ATPase inhibitor","INHIBITOR","ENSG00000105675","ATPase H+/K+ transporting subunit alpha","ATP4A","Small molecule","NCT04874935"
"57",3,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04546009","MONDO_0007254","breast cancer","CHEMBL4650316","GIREDESTRANT","Estrogen receptor alpha degrader","DEGRADER","ENSG00000091831","estrogen receptor 1","ESR1","Small molecule","NCT04546009"
"58",3,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01275677","EFO_0000305","breast carcinoma","CHEMBL359744","DOXORUBICIN HYDROCHLORIDE","DNA topoisomerase II alpha inhibitor","INHIBITOR","ENSG00000131747","DNA topoisomerase II alpha","TOP2A","Small molecule","NCT01275677"
"59",3,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02032823","MONDO_0007254","breast cancer","CHEMBL521686","OLAPARIB","PARP 1, 2 and 3 inhibitor","INHIBITOR","ENSG00000143799","poly(ADP-ribose) polymerase 2","PARP2","Small molecule","NCT02032823"
"60",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00459771","MONDO_0007254","breast cancer","CHEMBL1014","CANDESARTAN CILEXETIL","Type-1 angiotensin II receptor antagonist","ANTAGONIST","ENSG00000144891","angiotensin II receptor type 1","AGTR1","Small molecule","NCT00459771"
"61",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00127205","MONDO_0007254","breast cancer","CHEMBL3989569","IBANDRONATE SODIUM","Farnesyl diphosphate synthase inhibitor","INHIBITOR","ENSG00000160752","farnesyl diphosphate synthase","FDPS","Small molecule","NCT00127205"
"62",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01517802","MONDO_0007254","breast cancer","CHEMBL271227","ABIRATERONE ACETATE","Cytochrome P450 17A1 inhibitor","INHIBITOR","ENSG00000148795","cytochrome P450 family 17 subfamily A member 1","CYP17A1","Small molecule","NCT01517802"
"63",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00003771","MONDO_0007254","breast cancer","CHEMBL135","ESTRADIOL","Estrogen receptor alpha agonist","AGONIST","ENSG00000091831","estrogen receptor 1","ESR1","Small molecule","NCT00003771"
"64",3,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05774951","MONDO_0007254","breast cancer","CHEMBL4650365","CAMIZESTRANT","Estrogen receptor alpha degrader","DEGRADER","ENSG00000091831","estrogen receptor 1","ESR1","Small molecule","NCT05774951"
"65",3,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05429684","MONDO_0007254","breast cancer","CHEMBL3544956","PYROTINIB","Epidermal growth factor receptor erbB1 inhibitor","INHIBITOR","ENSG00000141736","epidermal growth factor receptor","EGFR","Small molecule","NCT05429684"
"66",3,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05122494","MONDO_0007254","breast cancer","CHEMBL3545111","HEMAY-022","Receptor protein-tyrosine kinase erbB-2 inhibitor","INHIBITOR","ENSG00000141736","erb-b2 receptor tyrosine kinase 2","ERBB2","Small molecule","NCT05122494"
"67",3,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05132582","MONDO_0007254","breast cancer","CHEMBL3989868","TUCATINIB","Receptor protein-tyrosine kinase erbB-2 inhibitor","INHIBITOR","ENSG00000141736","erb-b2 receptor tyrosine kinase 2","ERBB2","Small molecule","NCT05132582"
"68",3,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05646862","MONDO_0007254","breast cancer","CHEMBL4650215","INAVOLISIB","PI3-kinase p110-alpha subunit inhibitor","INHIBITOR","ENSG00000121879","phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha","PIK3CA","Small molecule","NCT05646862"
"69",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00003010","MONDO_0007254","breast cancer","CHEMBL279785","MARIMASTAT","Matrix metalloproteinase-2 inhibitor","INHIBITOR","ENSG00000149968","matrix metallopeptidase 2","MMP2","Small molecule","NCT00003010"
"70",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02032277","MONDO_0007254","breast cancer","CHEMBL506871","VELIPARIB","PARP 1, 2 and 3 inhibitor","INHIBITOR","ENSG00000143799","poly(ADP-ribose) polymerase family member 3","PARP3","Small molecule","NCT02032277"
"71",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00309491","MONDO_0007254","breast cancer","CHEMBL488","AMINOGLUTETHIMIDE","Cytochrome P450 11A1 inhibitor","INHIBITOR","ENSG00000137869","cytochrome P450 family 11 subfamily A member 1","CYP11A1","Small molecule","NCT00309491"
"72",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00002836","MONDO_0007254","breast cancer","CHEMBL44657","ETOPOSIDE","DNA topoisomerase II inhibitor","INHIBITOR","ENSG00000131747","DNA topoisomerase II beta","TOP2B","Small molecule","NCT00002836"
"73",3,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04869943","MONDO_0007254","breast cancer","CHEMBL1738889","ENOBOSARM","Androgen Receptor modulator","MODULATOR","ENSG00000169083","androgen receptor","AR","Small molecule","NCT04869943"
"74",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00083304","MONDO_0007254","breast cancer","CHEMBL18901","EFAPROXIRAL","Hemoglobin HbA negative modulator","NEGATIVE MODULATOR","ENSG00000206172","hemoglobin subunit beta","HBB","Small molecule","NCT00083304"
"75",3,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04305496","MONDO_0007254","breast cancer","CHEMBL2325741","CAPIVASERTIB","Serine/threonine-protein kinase AKT inhibitor","INHIBITOR","ENSG00000105221","AKT serine/threonine kinase 2","AKT2","Small molecule","NCT04305496"
"76",3,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00301925","MONDO_0007254","breast cancer","CHEMBL34259","METHOTREXATE","Dihydrofolate reductase inhibitor","INHIBITOR","ENSG00000228716","dihydrofolate reductase","DHFR","Small molecule","NCT00301925"
"77",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00357734","MONDO_0007254","breast cancer","CHEMBL939","GEFITINIB","Epidermal growth factor receptor erbB1 inhibitor","INHIBITOR","ENSG00000146648","epidermal growth factor receptor","EGFR","Small molecule","NCT00357734"
"78",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01492101","MONDO_0007254","breast cancer","CHEMBL3039558","ETIRINOTECAN PEGOL","DNA topoisomerase I inhibitor","INHIBITOR","ENSG00000198900","DNA topoisomerase I","TOP1","Small molecule","NCT01492101"
"79",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01480869","MONDO_0007254","breast cancer","CHEMBL1042","CHOLECALCIFEROL","Vitamin D receptor agonist","AGONIST","ENSG00000111424","vitamin D receptor","VDR","Small molecule","NCT01480869"
"80",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00878709","MONDO_0007254","breast cancer","CHEMBL180022","NERATINIB","Receptor protein-tyrosine kinase erbB-2 inhibitor","INHIBITOR","ENSG00000146648","erb-b2 receptor tyrosine kinase 2","ERBB2","Small molecule","NCT00878709"
"81",3,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04601116","MONDO_0007254","breast cancer","CHEMBL393220","ATORVASTATIN CALCIUM","HMG-CoA reductase inhibitor","INHIBITOR","ENSG00000113161","3-hydroxy-3-methylglutaryl-CoA reductase","HMGCR","Small molecule","NCT04601116"
"82",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00003032","MONDO_0007254","breast cancer","CHEMBL58","MITOXANTRONE","DNA topoisomerase II alpha inhibitor","INHIBITOR","ENSG00000131747","DNA topoisomerase II alpha","TOP2A","Small molecule","NCT00003032"
"83",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00152178","MONDO_0007254","breast cancer","CHEMBL20883","TEGAFUR","Thymidylate synthase inhibitor","INHIBITOR","ENSG00000176890","thymidylate synthetase","TYMS","Small molecule","NCT00152178"
"84",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00003893","MONDO_0007254","breast cancer","CHEMBL1417019","MITOXANTRONE HYDROCHLORIDE","DNA topoisomerase II alpha inhibitor","INHIBITOR","ENSG00000131747","DNA topoisomerase II alpha","TOP2A","Small molecule","NCT00003893"
"85",3,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04296370","MONDO_0007254","breast cancer","CHEMBL3545414","RIVOCERANIB MESYLATE","Vascular endothelial growth factor receptor 2 inhibitor","INHIBITOR","ENSG00000128052","kinase insert domain receptor","KDR","Small molecule","NCT04296370"
"86",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00002836","MONDO_0007254","breast cancer","CHEMBL513","CARMUSTINE","Glutathione reductase inhibitor","INHIBITOR","ENSG00000104687","glutathione-disulfide reductase","GSR","Small molecule","NCT00002836"
"87",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00196859","MONDO_0007254","breast cancer","CHEMBL997","IBANDRONIC ACID","Farnesyl diphosphate synthase inhibitor","INHIBITOR","ENSG00000160752","farnesyl diphosphate synthase","FDPS","Small molecule","NCT00196859"
"88",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00122356","MONDO_0007254","breast cancer","CHEMBL675","ALENDRONATE SODIUM","Farnesyl diphosphate synthase inhibitor","INHIBITOR","ENSG00000160752","farnesyl diphosphate synthase","FDPS","Small molecule","NCT00122356"
"89",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02594371","MONDO_0007254","breast cancer","CHEMBL4594298","ENCEQUIDAR","P-glycoprotein 1 inhibitor","INHIBITOR","ENSG00000085563","ATP binding cassette subfamily B member 1","ABCB1","Small molecule","NCT02594371"
"90",3,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03996265","MONDO_0007254","breast cancer","CHEMBL894","BUPROPION","Dopamine transporter inhibitor","INHIBITOR","ENSG00000142319","solute carrier family 6 member 3","SLC6A3","Small molecule","NCT03996265"
"91",3,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03778931","MONDO_0007254","breast cancer","CHEMBL4297509","ELACESTRANT","Estrogen receptor alpha degrader","DEGRADER","ENSG00000091831","estrogen receptor 1","ESR1","Small molecule","NCT03778931"
"92",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01856543","MONDO_0007254","breast cancer","CHEMBL1161","MOMETASONE FUROATE","Glucocorticoid receptor agonist","AGONIST","ENSG00000113580","nuclear receptor subfamily 3 group C member 1","NR3C1","Small molecule","NCT01856543"
"93",3,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00433420","MONDO_0007254","breast cancer","CHEMBL185","FLUOROURACIL","Thymidylate synthase inhibitor","INHIBITOR","ENSG00000176890","thymidylate synthetase","TYMS","Small molecule","NCT00433420"
"94",3,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03996265","MONDO_0007254","breast cancer","CHEMBL1698","BUPROPION HYDROCHLORIDE","Dopamine transporter inhibitor","INHIBITOR","ENSG00000103546","solute carrier family 6 member 3","SLC6A3","Small molecule","NCT03996265"
"95",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02429427","MONDO_0007254","breast cancer","CHEMBL118","CELECOXIB","Cyclooxygenase-2 inhibitor","INHIBITOR","ENSG00000073756","prostaglandin-endoperoxide synthase 2","PTGS2","Small molecule","NCT02429427"
"96",3,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04601116","MONDO_0007254","breast cancer","CHEMBL1487","ATORVASTATIN","HMG-CoA reductase inhibitor","INHIBITOR","ENSG00000113161","3-hydroxy-3-methylglutaryl-CoA reductase","HMGCR","Small molecule","NCT04601116"
"97",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01517802","MONDO_0007254","breast cancer","CHEMBL635","PREDNISONE","Glucocorticoid receptor agonist","AGONIST","ENSG00000113580","nuclear receptor subfamily 3 group C member 1","NR3C1","Small molecule","NCT01517802"
"98",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00003771","MONDO_0007254","breast cancer","CHEMBL1201146","NORETHINDRONE ACETATE","Progesterone receptor agonist","AGONIST","ENSG00000082175","progesterone receptor","PGR","Small molecule","NCT00003771"
"99",3,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04296370","MONDO_0007254","breast cancer","CHEMBL3186534","RIVOCERANIB","Vascular endothelial growth factor receptor 2 inhibitor","INHIBITOR","ENSG00000128052","kinase insert domain receptor","KDR","Small molecule","NCT04296370"
"100",3,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03794388","MONDO_0007254","breast cancer","CHEMBL1059","PREGABALIN","Voltage-gated calcium channel modulator","MODULATOR","ENSG00000196557","calcium voltage-gated channel auxiliary subunit alpha2delta 1","CACNA2D1","Small molecule","NCT03794388"
"101",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01237327","MONDO_0007254","breast cancer","CHEMBL1201139","MEGESTROL ACETATE","Progesterone receptor agonist","AGONIST","ENSG00000082175","progesterone receptor","PGR","Small molecule","NCT01237327"
"102",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00003906","MONDO_0007254","breast cancer","CHEMBL81","RALOXIFENE","Estrogen receptor beta modulator","MODULATOR","ENSG00000140009","estrogen receptor 2","ESR2","Small molecule","NCT00003906"
"103",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01224678","MONDO_0007254","breast cancer","CHEMBL1536","ERGOCALCIFEROL","Vitamin D receptor agonist","AGONIST","ENSG00000111424","vitamin D receptor","VDR","Small molecule","NCT01224678"
"104",3,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03794388","MONDO_0007254","breast cancer","CHEMBL294199","CAPSAICIN","Vanilloid receptor opener","OPENER","ENSG00000196689","transient receptor potential cation channel subfamily V member 1","TRPV1","Small molecule","NCT03794388"
"105",3,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00122356","MONDO_0007254","breast cancer","CHEMBL870","ALENDRONIC ACID","Farnesyl diphosphate synthase inhibitor","INHIBITOR","ENSG00000160752","farnesyl diphosphate synthase","FDPS","Small molecule","NCT00122356"
"106",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00096434","EFO_0006861","male breast carcinoma","CHEMBL1200485","SORAFENIB TOSYLATE","Vascular endothelial growth factor receptor inhibitor","INHIBITOR","ENSG00000165731","fms related receptor tyrosine kinase 1","FLT1","Small molecule","NCT00096434"
"107",2,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03330847","MONDO_0007254","breast cancer","CHEMBL4285417","CERALASERTIB","Serine-protein kinase ATR inhibitor","INHIBITOR","ENSG00000175054","ATR serine/threonine kinase","ATR","Small molecule","NCT03330847"
"108",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05181033","MONDO_0007254","breast cancer","CHEMBL1289601","LENVATINIB","Vascular endothelial growth factor receptor inhibitor","INHIBITOR","ENSG00000102755","fms related receptor tyrosine kinase 4","FLT4","Small molecule","NCT05181033"
"109",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04891068","MONDO_0007254","breast cancer","CHEMBL1489","AZACITIDINE","DNA (cytosine-5)-methyltransferase 3A inhibitor","INHIBITOR","ENSG00000119772","DNA methyltransferase 3 alpha","DNMT3A","Small molecule","NCT04891068"
"110",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03084536","MONDO_0007254","breast cancer","CHEMBL655","MIDAZOLAM","GABA-A receptor; anion channel positive allosteric modulator","POSITIVE ALLOSTERIC MODULATOR","ENSG00000022355","gamma-aminobutyric acid type A receptor subunit alpha1","GABRA1","Small molecule","NCT03084536"
"111",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01658462","MONDO_0007254","breast cancer","CHEMBL502835","NINTEDANIB","Vascular endothelial growth factor receptor inhibitor","INHIBITOR","ENSG00000113721","fms related receptor tyrosine kinase 4","FLT4","Small molecule","NCT01658462"
"112",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04603911","MONDO_0007254","breast cancer","CHEMBL679","EPINEPHRINE","Adrenergic receptor agonist","AGONIST","ENSG00000120907","adrenoceptor beta 3","ADRB3","Small molecule","NCT04603911"
"113",2,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02642094","MONDO_0007254","breast cancer","CHEMBL413","SIROLIMUS","FK506-binding protein 1A inhibitor","INHIBITOR","ENSG00000088832","FKBP prolyl isomerase 1A","FKBP1A","Small molecule","NCT02642094"
"114",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01118624","EFO_0000305","breast carcinoma","CHEMBL1201746","PRALATREXATE","Dihydrofolate reductase inhibitor","INHIBITOR","ENSG00000228716","dihydrofolate reductase","DHFR","Small molecule","NCT01118624"
"115",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02441946","EFO_0000305","breast carcinoma","CHEMBL841","LOPERAMIDE","Mu opioid receptor agonist","AGONIST","ENSG00000112038","opioid receptor mu 1","OPRM1","Small molecule","NCT02441946"
"116",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00513695","EFO_0006861","male breast carcinoma","CHEMBL535","SUNITINIB","Macrophage colony stimulating factor receptor inhibitor","INHIBITOR","ENSG00000122025","colony stimulating factor 1 receptor","CSF1R","Small molecule","NCT00513695"
"117",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00494481","MONDO_0007254","breast cancer","CHEMBL24828","VANDETANIB","Epidermal growth factor receptor inhibitor","INHIBITOR","ENSG00000141736","erb-b2 receptor tyrosine kinase 3","ERBB3","Small molecule","NCT00494481"
"118",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02338245","MONDO_0007254","breast cancer","CHEMBL2103842","VARLITINIB","Epidermal growth factor receptor erbB1 inhibitor","INHIBITOR","ENSG00000146648","epidermal growth factor receptor","EGFR","Small molecule","NCT02338245"
"119",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00513695","EFO_0006861","male breast carcinoma","CHEMBL1567","SUNITINIB MALATE","Macrophage colony stimulating factor receptor inhibitor","INHIBITOR","ENSG00000122025","colony stimulating factor 1 receptor","CSF1R","Small molecule","NCT00513695"
"120",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04090567","EFO_0000305","breast carcinoma","CHEMBL491473","CEDIRANIB","Vascular endothelial growth factor receptor inhibitor","INHIBITOR","ENSG00000157404","fms related receptor tyrosine kinase 4","FLT4","Small molecule","NCT04090567"
"121",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03765983","MONDO_0007254","breast cancer","CHEMBL3813842","PAXALISIB","PI3-kinase class I inhibitor","INHIBITOR","ENSG00000145675","phosphoinositide-3-kinase regulatory subunit 1","PIK3R1","Small molecule","NCT03765983"
"122",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01639248","MONDO_0007254","breast cancer","CHEMBL482968","ENMD-2076","Serine/threonine-protein kinase Aurora-A inhibitor","INHIBITOR","ENSG00000087586","aurora kinase A","AURKA","Small molecule","NCT01639248"
"123",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03084536","MONDO_0007254","breast cancer","CHEMBL112","ACETAMINOPHEN","Vanilloid receptor opener","OPENER","ENSG00000196689","transient receptor potential cation channel subfamily V member 1","TRPV1","Small molecule","NCT03084536"
"124",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05089643","EFO_0005537","triple-negative breast cancer","CHEMBL4303201","ANLOTINIB","Stem cell growth factor receptor inhibitor","INHIBITOR","ENSG00000113721","KIT proto-oncogene, receptor tyrosine kinase","KIT","Small molecule","NCT05089643"
"125",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01693549","MONDO_0007254","breast cancer","CHEMBL1201748","CABAZITAXEL","Tubulin inhibitor","INHIBITOR","ENSG00000188229","tubulin beta 3 class III","TUBB3","Small molecule","NCT01693549"
"126",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01042379","EFO_0005537","triple-negative breast cancer","CHEMBL3137320","TALAZOPARIB","Poly [ADP-ribose] polymerase 2 inhibitor","INHIBITOR","ENSG00000143799","poly(ADP-ribose) polymerase 2","PARP2","Small molecule","NCT01042379"
"127",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03094052","EFO_0000304","breast adenocarcinoma","CHEMBL2146146","ATROPINE SULFATE","Muscarinic acetylcholine receptor M2 antagonist","ANTAGONIST","ENSG00000133019","cholinergic receptor muscarinic 2","CHRM2","Small molecule","NCT03094052"
"128",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00464516","MONDO_0007254","breast cancer","CHEMBL1230314","ESTETROL","Estrogen receptor agonist","AGONIST","ENSG00000140009","estrogen receptor 1","ESR1","Small molecule","NCT00464516"
"129",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00148707","MONDO_0007254","breast cancer","CHEMBL2108628","PACLITAXEL POLIGLUMEX","Tubulin stabiliser","STABILISER","ENSG00000188229","tubulin beta 2A class IIa","TUBB2A","Small molecule","NCT00148707"
"130",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01042379","EFO_0005537","triple-negative breast cancer","CHEMBL3813873","PEXIDARTINIB","Tyrosine-protein kinase receptor FLT3 inhibitor","INHIBITOR","ENSG00000122025","fms related receptor tyrosine kinase 3","FLT3","Small molecule","NCT01042379"
"131",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02910219","MONDO_0007254","breast cancer","CHEMBL2108184","CROFELEMER","Anoctamin-1 blocker","BLOCKER","ENSG00000131620","anoctamin 1","ANO1","Small molecule","NCT02910219"
"132",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00509587","MONDO_0007254","breast cancer","CHEMBL477772","PAZOPANIB","Vascular endothelial growth factor receptor inhibitor","INHIBITOR","ENSG00000077782","kinase insert domain receptor","KDR","Small molecule","NCT00509587"
"133",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00054275","MONDO_0007254","breast cancer","CHEMBL553","ERLOTINIB","Epidermal growth factor receptor erbB1 inhibitor","INHIBITOR","ENSG00000146648","epidermal growth factor receptor","EGFR","Small molecule","NCT00054275"
"134",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02418689","MONDO_0007254","breast cancer","CHEMBL3545154","POZIOTINIB","Epidermal growth factor receptor inhibitor","INHIBITOR","ENSG00000141736","erb-b2 receptor tyrosine kinase 2","ERBB2","Small molecule","NCT02418689"
"135",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00853996","MONDO_0007254","breast cancer","CHEMBL68055","ACOLBIFENE","Estrogen receptor modulator","MODULATOR","ENSG00000140009","estrogen receptor 2","ESR2","Small molecule","NCT00853996"
"136",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00450866","MONDO_0007254","breast cancer","CHEMBL94657","PATUPILONE","Tubulin stabiliser","STABILISER","ENSG00000188229","tubulin beta 3 class III","TUBB3","Small molecule","NCT00450866"
"137",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01332630","MONDO_0007254","breast cancer","CHEMBL1620","DIPHENHYDRAMINE HYDROCHLORIDE","Histamine H1 receptor antagonist","ANTAGONIST","ENSG00000196639","histamine receptor H1","HRH1","Small molecule","NCT01332630"
"138",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00306631","MONDO_0007254","breast cancer","CHEMBL52885","ENMD-981693","Fibroblast growth factor receptor inhibitor","INHIBITOR","ENSG00000010810","fibroblast growth factor receptor 3","FGFR3","Small molecule","NCT00306631"
"139",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05336721","EFO_0005537","triple-negative breast cancer","CHEMBL5095033","IBCASERTIB","Vascular endothelial growth factor receptor inhibitor","INHIBITOR","ENSG00000102755","fms related receptor tyrosine kinase 4","FLT4","Small molecule","NCT05336721"
"140",2,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03202316","EFO_0000305","breast carcinoma","CHEMBL2146883","COBIMETINIB","Dual specificity mitogen-activated protein kinase kinase 1 inhibitor","INHIBITOR","ENSG00000169032","mitogen-activated protein kinase kinase 1","MAP2K1","Small molecule","NCT03202316"
"141",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01009918","MONDO_0007254","breast cancer","CHEMBL1237","LISINOPRIL","Angiotensin-converting enzyme inhibitor","INHIBITOR","ENSG00000159640","angiotensin I converting enzyme","ACE","Small molecule","NCT01009918"
"142",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00325234","MONDO_0007254","breast cancer","CHEMBL225072","PEMETREXED","GAR transformylase inhibitor","INHIBITOR","ENSG00000176890","phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase","GART","Small molecule","NCT00325234"
"143",2,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02876302","EFO_1000984","inflammatory breast carcinoma","CHEMBL1789941","RUXOLITINIB","Tyrosine-protein kinase JAK2 inhibitor","INHIBITOR","ENSG00000096968","Janus kinase 2","JAK2","Small molecule","NCT02876302"
"144",2,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04032080","MONDO_0007254","breast cancer","CHEMBL4297181","SAMOTOLISIB","PI3-kinase class I inhibitor","INHIBITOR","ENSG00000198793","phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma","PIK3CG","Small molecule","NCT04032080"
"145",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04821141","MONDO_0007254","breast cancer","CHEMBL1201649","ESTROGENS, CONJUGATED","Estrogen receptor agonist","AGONIST","ENSG00000140009","estrogen receptor 2","ESR2","Small molecule","NCT04821141"
"146",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02370238","MONDO_0007254","breast cancer","CHEMBL191413","REPARIXIN","Interleukin-8 receptor A modulator","MODULATOR","ENSG00000180871","C-X-C motif chemokine receptor 1","CXCR1","Small molecule","NCT02370238"
"147",2,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03650894","EFO_0000305","breast carcinoma","CHEMBL409","BICALUTAMIDE","Androgen Receptor antagonist","ANTAGONIST","ENSG00000169083","androgen receptor","AR","Small molecule","NCT03650894"
"148",2,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02860000","EFO_0000305","breast carcinoma","CHEMBL483158","ALISERTIB","Serine/threonine-protein kinase Aurora-A inhibitor","INHIBITOR","ENSG00000087586","aurora kinase A","AURKA","Small molecule","NCT02860000"
"149",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02177175","MONDO_0007254","breast cancer","CHEMBL723","CARVEDILOL","Adrenergic receptor alpha-1 antagonist","ANTAGONIST","ENSG00000043591","adrenoceptor alpha 1D","ADRA1D","Small molecule","NCT02177175"
"150",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03094052","EFO_0000304","breast adenocarcinoma","CHEMBL1200665","DIPHENOXYLATE HYDROCHLORIDE","Mu opioid receptor agonist","AGONIST","ENSG00000112038","opioid receptor mu 1","OPRM1","Small molecule","NCT03094052"
"151",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05727098","MONDO_0007254","breast cancer","CHEMBL742","KETAMINE","Glutamate [NMDA] receptor negative allosteric modulator","NEGATIVE ALLOSTERIC MODULATOR","ENSG00000176884","glutamate ionotropic receptor NMDA type subunit 2A","GRIN2A","Small molecule","NCT05727098"
"152",2,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01471106","MONDO_0007254","breast cancer","CHEMBL1421","DASATINIB","SRC inhibitor","INHIBITOR","ENSG00000113721","fyn related Src family tyrosine kinase","FRK","Small molecule","NCT01471106"
"153",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01068704","MONDO_0007254","breast cancer","CHEMBL3545396","BMS-690514","Receptor protein-tyrosine kinase erbB-2 inhibitor","INHIBITOR","ENSG00000141736","erb-b2 receptor tyrosine kinase 2","ERBB2","Small molecule","NCT01068704"
"154",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01594177","MONDO_0007254","breast cancer","CHEMBL1173655","AFATINIB","Receptor protein-tyrosine kinase erbB-2 inhibitor","INHIBITOR","ENSG00000178568","erb-b2 receptor tyrosine kinase 2","ERBB2","Small molecule","NCT01594177"
"155",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05560334","MONDO_0007254","breast cancer","CHEMBL4297522","PEMIGATINIB","Fibroblast growth factor receptor 3 inhibitor","INHIBITOR","ENSG00000077782","fibroblast growth factor receptor 3","FGFR3","Small molecule","NCT05560334"
"156",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00338728","MONDO_0007254","breast cancer","CHEMBL1642","IMATINIB MESYLATE","Tyrosine-protein kinase ABL inhibitor","INHIBITOR","ENSG00000097007","ABL proto-oncogene 1, non-receptor tyrosine kinase","ABL1","Small molecule","NCT00338728"
"157",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00262834","MONDO_0007254","breast cancer","CHEMBL98","VORINOSTAT","Histone deacetylase 6 inhibitor","INHIBITOR","ENSG00000094631","histone deacetylase 6","HDAC6","Small molecule","NCT00262834"
"158",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01763931","MONDO_0007254","breast cancer","CHEMBL1751","DIGOXIN","Sodium/potassium-transporting ATPase inhibitor","INHIBITOR","ENSG00000163399","ATPase Na+/K+ transporting subunit alpha 4","ATP1A4","Small molecule","NCT01763931"
"159",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01740336","MONDO_0007254","breast cancer","CHEMBL521851","PICTILISIB","PI3-kinase class I inhibitor","INHIBITOR","ENSG00000145675","phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta","PIK3CB","Small molecule","NCT01740336"
"160",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04837209","MONDO_0007254","breast cancer","CHEMBL1094636","NIRAPARIB","Poly [ADP-ribose] polymerase-1 inhibitor","INHIBITOR","ENSG00000143799","poly(ADP-ribose) polymerase 1","PARP1","Small molecule","NCT04837209"
"161",2,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02788981","MONDO_0007254","breast cancer","CHEMBL1276308","MIFEPRISTONE","Glucocorticoid receptor antagonist","ANTAGONIST","ENSG00000113580","nuclear receptor subfamily 3 group C member 1","NR3C1","Small molecule","NCT02788981"
"162",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03931928","MONDO_0007254","breast cancer","CHEMBL489","AFIMOXIFENE","Estrogen receptor modulator","MODULATOR","ENSG00000140009","estrogen receptor 1","ESR1","Small molecule","NCT03931928"
"163",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01009918","MONDO_0007254","breast cancer","CHEMBL1201167","CARVEDILOL PHOSPHATE","Adrenergic receptor alpha-1 antagonist","ANTAGONIST","ENSG00000120907","adrenoceptor alpha 1B","ADRA1B","Small molecule","NCT01009918"
"164",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01847001","MONDO_0007254","breast cancer","CHEMBL27","PROPRANOLOL","Beta-2 adrenergic receptor antagonist","ANTAGONIST","ENSG00000043591","adrenoceptor beta 2","ADRB2","Small molecule","NCT01847001"
"165",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01437566","MONDO_0007254","breast cancer","CHEMBL1922094","APITOLISIB","PI3-kinase class I inhibitor","INHIBITOR","ENSG00000198793","phosphoinositide-3-kinase regulatory subunit 5","PIK3R5","Small molecule","NCT01437566"
"166",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02273973","MONDO_0007254","breast cancer","CHEMBL2387080","TASELISIB","PI3-kinase class I inhibitor","INHIBITOR","ENSG00000145675","phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha","PIK3CA","Small molecule","NCT02273973"
"167",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00645177","MONDO_0007254","breast cancer","CHEMBL223360","LINIFANIB","Macrophage colony stimulating factor receptor inhibitor","INHIBITOR","ENSG00000122025","colony stimulating factor 1 receptor","CSF1R","Small molecule","NCT00645177"
"168",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00033384","MONDO_0007254","breast cancer","CHEMBL105442","CI-1040","Dual specificity mitogen-activated protein kinase kinase 2 inhibitor","INHIBITOR","ENSG00000126934","mitogen-activated protein kinase kinase 2","MAP2K2","Small molecule","NCT00033384"
"169",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03801369","EFO_0005537","triple-negative breast cancer","CHEMBL1614701","SELUMETINIB","Dual specificity mitogen-activated protein kinase kinase 2 inhibitor","INHIBITOR","ENSG00000169032","mitogen-activated protein kinase kinase 2","MAP2K2","Small molecule","NCT03801369"
"170",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00509587","MONDO_0007254","breast cancer","CHEMBL1201733","PAZOPANIB HYDROCHLORIDE","Fibroblast growth factor receptor 3 inhibitor","INHIBITOR","ENSG00000077782","fibroblast growth factor receptor 3","FGFR3","Small molecule","NCT00509587"
"171",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00288249","MONDO_0007254","breast cancer","CHEMBL2304041","SAGOPILONE","Tubulin stabiliser","STABILISER","ENSG00000188229","tubulin beta 8 class VIII","TUBB8","Small molecule","NCT00288249"
"172",2,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03562832","MONDO_0007254","breast cancer","CHEMBL3644587","2X-121","Tankyrase 1/2 inhibitor","INHIBITOR","ENSG00000143799","tankyrase","TNKS","Small molecule","NCT03562832"
"173",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03012477","MONDO_0007254","breast cancer","CHEMBL1976040","ADAVOSERTIB","Serine/threonine-protein kinase WEE1 inhibitor","INHIBITOR","ENSG00000166483","WEE1 G2 checkpoint kinase","WEE1","Small molecule","NCT03012477"
"174",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00005879","MONDO_0007254","breast cancer","CHEMBL226267","ARZOXIFENE","Estrogen receptor modulator","MODULATOR","ENSG00000140009","estrogen receptor 2","ESR2","Small molecule","NCT00005879"
"175",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01990209","MONDO_0007254","breast cancer","CHEMBL1921976","ORTERONEL","Cytochrome P450 17A1 inhibitor","INHIBITOR","ENSG00000148795","cytochrome P450 family 17 subfamily A member 1","CYP17A1","Small molecule","NCT01990209"
"176",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04756765","MONDO_0007254","breast cancer","CHEMBL3137318","TALAZOPARIB TOSYLATE","Poly [ADP-ribose] polymerase 2 inhibitor","INHIBITOR","ENSG00000129484","poly(ADP-ribose) polymerase 2","PARP2","Small molecule","NCT04756765"
"177",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02053636","MONDO_0007254","breast cancer","CHEMBL2220486","LUCITANIB","Fibroblast growth factor receptor 1 inhibitor","INHIBITOR","ENSG00000102755","fibroblast growth factor receptor 1","FGFR1","Small molecule","NCT02053636"
"178",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00429572","MONDO_0007254","breast cancer","CHEMBL1096882","FLUDARABINE PHOSPHATE","DNA polymerase (alpha/delta/epsilon) inhibitor","INHIBITOR","ENSG00000167325","DNA polymerase alpha 1, catalytic subunit","POLA1","Small molecule","NCT00429572"
"179",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01147484","MONDO_0007254","breast cancer","CHEMBL1230609","FORETINIB","Stem cell growth factor receptor inhibitor","INHIBITOR","ENSG00000113721","KIT proto-oncogene, receptor tyrosine kinase","KIT","Small molecule","NCT01147484"
"180",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05190770","MONDO_0007254","breast cancer","CHEMBL1504","TRIAMCINOLONE ACETONIDE","Glucocorticoid receptor agonist","AGONIST","ENSG00000113580","nuclear receptor subfamily 3 group C member 1","NR3C1","Small molecule","NCT05190770"
"181",2,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02299999","MONDO_0007254","breast cancer","CHEMBL3184679","AZD-4547","Fibroblast growth factor receptor inhibitor","INHIBITOR","ENSG00000068078","fibroblast growth factor receptor 4","FGFR4","Small molecule","NCT02299999"
"182",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00198250","MONDO_0007254","breast cancer","CHEMBL637","VENLAFAXINE","Norepinephrine transporter inhibitor","INHIBITOR","ENSG00000108576","solute carrier family 6 member 2","SLC6A2","Small molecule","NCT00198250"
"183",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04542135","MONDO_0007254","breast cancer","CHEMBL15770","SULINDAC","Cyclooxygenase inhibitor","INHIBITOR","ENSG00000073756","prostaglandin-endoperoxide synthase 2","PTGS2","Small molecule","NCT04542135"
"184",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02839668","MONDO_0007254","breast cancer","CHEMBL517712","ATROPINE","Muscarinic acetylcholine receptor M2 antagonist","ANTAGONIST","ENSG00000133019","cholinergic receptor muscarinic 2","CHRM2","Small molecule","NCT02839668"
"185",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02402764","MONDO_0007254","breast cancer","CHEMBL3545185","SELINEXOR","Exportin-1 inhibitor","INHIBITOR","ENSG00000082898","exportin 1","XPO1","Small molecule","NCT02402764"
"186",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01262027","MONDO_0007254","breast cancer","CHEMBL522892","DOVITINIB","Fibroblast growth factor receptor 3 inhibitor","INHIBITOR","ENSG00000113721","fibroblast growth factor receptor 3","FGFR3","Small molecule","NCT01262027"
"187",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00077363","MONDO_0007254","breast cancer","CHEMBL289228","TIPIFARNIB","Protein farnesyltransferase inhibitor","INHIBITOR","ENSG00000168522","farnesyltransferase, CAAX box, alpha","FNTA","Small molecule","NCT00077363"
"188",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00006007","MONDO_0007254","breast cancer","CHEMBL2360464","PEMETREXED DISODIUM","Dihydrofolate reductase inhibitor","INHIBITOR","ENSG00000176890","dihydrofolate reductase","DHFR","Small molecule","NCT00006007"
"189",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04588935","MONDO_0007254","breast cancer","CHEMBL645","BISOPROLOL","Beta-1 adrenergic receptor antagonist","ANTAGONIST","ENSG00000043591","adrenoceptor beta 1","ADRB1","Small molecule","NCT04588935"
"190",2,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04059484","MONDO_0007254","breast cancer","CHEMBL4475463","AMCENESTRANT","Estrogen receptor alpha degrader","DEGRADER","ENSG00000091831","estrogen receptor 1","ESR1","Small molecule","NCT04059484"
"191",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02689427","EFO_0005537","triple-negative breast cancer","CHEMBL1082407","ENZALUTAMIDE","Androgen Receptor antagonist","ANTAGONIST","ENSG00000169083","androgen receptor","AR","Small molecule","NCT02689427"
"192",2,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04024436","MONDO_0007254","breast cancer","CHEMBL3701238","FUTIBATINIB","Fibroblast growth factor receptor inhibitor","INHIBITOR","ENSG00000068078","fibroblast growth factor receptor 4","FGFR4","Small molecule","NCT04024436"
"193",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00063102","MONDO_0007254","breast cancer","CHEMBL20684","ABT-751","Tubulin beta inhibitor","INHIBITOR","ENSG00000188229","tubulin beta 8B","TUBB8B","Small molecule","NCT00063102"
"194",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04551495","EFO_0000553","invasive lobular carcinoma","CHEMBL1983268","ENTRECTINIB","Neurotrophic tyrosine kinase receptor inhibitor","INHIBITOR","ENSG00000047936","neurotrophic receptor tyrosine kinase 2","NTRK2","Small molecule","NCT04551495"
"195",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03328884","MONDO_0007254","breast cancer","CHEMBL481","IRINOTECAN","DNA topoisomerase I inhibitor","INHIBITOR","ENSG00000198900","DNA topoisomerase I","TOP1","Small molecule","NCT03328884"
"196",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00028639","MONDO_0007254","breast cancer","CHEMBL325041","BORTEZOMIB","26S proteosome inhibitor","INHIBITOR","ENSG00000173692","proteasome 20S subunit beta 5","PSMB5","Small molecule","NCT00028639"
"197",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00166543","MONDO_0007254","breast cancer","CHEMBL3545211","SR16234","Estrogen receptor alpha antagonist","ANTAGONIST","ENSG00000091831","estrogen receptor 1","ESR1","Small molecule","NCT00166543"
"198",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03575065","MONDO_0007254","breast cancer","CHEMBL4112930","PAMIPARIB","Poly [ADP-ribose] polymerase 2 inhibitor","INHIBITOR","ENSG00000143799","poly(ADP-ribose) polymerase 2","PARP2","Small molecule","NCT03575065"
"199",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00559507","EFO_0006861","male breast carcinoma","CHEMBL217092","SARACATINIB","Tyrosine-protein kinase SRC inhibitor","INHIBITOR","ENSG00000097007","SRC proto-oncogene, non-receptor tyrosine kinase","SRC","Small molecule","NCT00559507"
"200",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00664781","Orphanet_145","Hereditary breast and ovarian cancer syndrome","CHEMBL1173055","RUCAPARIB","PARP 1, 2 and 3 inhibitor","INHIBITOR","ENSG00000143799","poly(ADP-ribose) polymerase 2","PARP2","Small molecule","NCT00664781"
"201",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01042379","EFO_0005537","triple-negative breast cancer","CHEMBL2103879","GANETESPIB","Heat shock protein HSP90 inhibitor","INHIBITOR","ENSG00000080824","heat shock protein 90 alpha family class A member 1","HSP90AA1","Small molecule","NCT01042379"
"202",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05090358","MONDO_0007254","breast cancer","CHEMBL4594217","CANAGLIFLOZIN","Sodium/glucose cotransporter 2 inhibitor","INHIBITOR","ENSG00000140675","solute carrier family 5 member 2","SLC5A2","Small molecule","NCT05090358"
"203",2,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04432454","MONDO_0007254","breast cancer","CHEMBL328190","LASOFOXIFENE","Estrogen receptor modulator","MODULATOR","ENSG00000140009","estrogen receptor 2","ESR2","Small molecule","NCT04432454"
"204",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04862585","MONDO_0004658","breast carcinoma in situ","CHEMBL902","FAMOTIDINE","Histamine H2 receptor antagonist","ANTAGONIST","ENSG00000113749","histamine receptor H2","HRH2","Small molecule","NCT04862585"
"205",2,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01441947","MONDO_0007254","breast cancer","CHEMBL2105717","CABOZANTINIB","Hepatocyte growth factor receptor inhibitor","INHIBITOR","ENSG00000128052","MET proto-oncogene, receptor tyrosine kinase","MET","Small molecule","NCT01441947"
"206",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04821141","MONDO_0007254","breast cancer","CHEMBL46740","BAZEDOXIFENE","Estrogen receptor modulator","MODULATOR","ENSG00000140009","estrogen receptor 2","ESR2","Small molecule","NCT04821141"
"207",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01332630","MONDO_0007254","breast cancer","CHEMBL1790041","RANITIDINE","Histamine H2 receptor antagonist","ANTAGONIST","ENSG00000113749","histamine receptor H2","HRH2","Small molecule","NCT01332630"
"208",2,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03454529","EFO_0000305","breast carcinoma","CHEMBL1064","SIMVASTATIN","HMG-CoA reductase inhibitor","INHIBITOR","ENSG00000113161","3-hydroxy-3-methylglutaryl-CoA reductase","HMGCR","Small molecule","NCT03454529"
"209",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01277757","EFO_0000305","breast carcinoma","CHEMBL1079175","MK-2206","Serine/threonine-protein kinase AKT inhibitor","INHIBITOR","ENSG00000105221","AKT serine/threonine kinase 1","AKT1","Small molecule","NCT01277757"
"210",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00416403","MONDO_0007254","breast cancer","CHEMBL2218894","FLUVASTATIN SODIUM","HMG-CoA reductase inhibitor","INHIBITOR","ENSG00000113161","3-hydroxy-3-methylglutaryl-CoA reductase","HMGCR","Small molecule","NCT00416403"
"211",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00198250","MONDO_0007254","breast cancer","CHEMBL1201066","VENLAFAXINE HYDROCHLORIDE","Norepinephrine transporter inhibitor","INHIBITOR","ENSG00000108576","solute carrier family 6 member 2","SLC6A2","Small molecule","NCT00198250"
"212",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01332630","MONDO_0007254","breast cancer","CHEMBL657","DIPHENHYDRAMINE","Histamine H1 receptor antagonist","ANTAGONIST","ENSG00000196639","histamine receptor H1","HRH1","Small molecule","NCT01332630"
"213",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01965522","MONDO_0007254","breast cancer","CHEMBL45","MELATONIN","Melatonin receptor agonist","AGONIST","ENSG00000168412","melatonin receptor 1B","MTNR1B","Small molecule","NCT01965522"
"214",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01964924","EFO_0005537","triple-negative breast cancer","CHEMBL3137336","UPROSERTIB","Serine/threonine-protein kinase AKT inhibitor","INHIBITOR","ENSG00000105221","AKT serine/threonine kinase 2","AKT2","Small molecule","NCT01964924"
"215",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03084536","MONDO_0007254","breast cancer","CHEMBL940","GABAPENTIN","Voltage-gated calcium channel modulator","MODULATOR","ENSG00000196557","calcium voltage-gated channel auxiliary subunit alpha2delta 1","CACNA2D1","Small molecule","NCT03084536"
"216",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01381874","MONDO_0007254","breast cancer","CHEMBL131","PREDNISOLONE","Glucocorticoid receptor agonist","AGONIST","ENSG00000113580","nuclear receptor subfamily 3 group C member 1","NR3C1","Small molecule","NCT01381874"
"217",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05186545","MONDO_0007254","breast cancer","CHEMBL4297190","SURUFATINIB","Vascular endothelial growth factor receptor inhibitor","INHIBITOR","ENSG00000077782","fms related receptor tyrosine kinase 1","FLT1","Small molecule","NCT05186545"
"218",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01964924","EFO_0005537","triple-negative breast cancer","CHEMBL2103875","TRAMETINIB","Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor","INHIBITOR","ENSG00000126934","mitogen-activated protein kinase kinase 1","MAP2K1","Small molecule","NCT01964924"
"219",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00005817","EFO_0006861","male breast carcinoma","CHEMBL2107313","BECATECARIN","DNA topoisomerase I inhibitor","INHIBITOR","ENSG00000131747","DNA topoisomerase I","TOP1","Small molecule","NCT00005817"
"220",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02839668","MONDO_0007254","breast cancer","CHEMBL278020","NEOSTIGMINE","Acetylcholinesterase inhibitor","INHIBITOR","ENSG00000087085","acetylcholinesterase (Yt blood group)","ACHE","Small molecule","NCT02839668"
"221",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01004081","MONDO_0007254","breast cancer","CHEMBL467399","BIIB021","Heat shock protein HSP90 inhibitor","INHIBITOR","ENSG00000080824","heat shock protein 90 alpha family class B member 1","HSP90AB1","Small molecule","NCT01004081"
"222",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00555919","MONDO_0007254","breast cancer","CHEMBL146032","LONAPRISAN","Progesterone receptor antagonist","ANTAGONIST","ENSG00000082175","progesterone receptor","PGR","Small molecule","NCT00555919"
"223",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03032406","MONDO_0007254","breast cancer","CHEMBL1535","HYDROXYCHLOROQUINE","Toll-like receptor 9 antagonist","ANTAGONIST","ENSG00000196664","toll like receptor 9","TLR9","Small molecule","NCT03032406"
"224",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04356209","MONDO_0007254","breast cancer","CHEMBL1144","PRAVASTATIN","HMG-CoA reductase inhibitor","INHIBITOR","ENSG00000113161","3-hydroxy-3-methylglutaryl-CoA reductase","HMGCR","Small molecule","NCT04356209"
"225",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01422408","EFO_0000305","breast carcinoma","CHEMBL1501","FLUOCINONIDE","Glucocorticoid receptor agonist","AGONIST","ENSG00000113580","nuclear receptor subfamily 3 group C member 1","NR3C1","Small molecule","NCT01422408"
"226",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02595372","EFO_0000305","breast carcinoma","CHEMBL1503","OMEPRAZOLE","Potassium-transporting ATPase inhibitor","INHIBITOR","ENSG00000105675","ATPase H+/K+ transporting subunit alpha","ATP4A","Small molecule","NCT02595372"
"227",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00736970","MONDO_0007254","breast cancer","CHEMBL2103839","RIDAFOROLIMUS","Serine/threonine-protein kinase mTOR inhibitor","INHIBITOR","ENSG00000198793","mechanistic target of rapamycin kinase","MTOR","Small molecule","NCT00736970"
"228",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00079118","MONDO_0007254","breast cancer","CHEMBL3989514","IRINOTECAN HYDROCHLORIDE","DNA topoisomerase I inhibitor","INHIBITOR","ENSG00000198900","DNA topoisomerase I","TOP1","Small molecule","NCT00079118"
"229",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00777049","MONDO_0007254","breast cancer","CHEMBL483254","PANOBINOSTAT","Histone deacetylase inhibitor","INHIBITOR","ENSG00000116478","histone deacetylase 3","HDAC3","Small molecule","NCT00777049"
"230",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00376688","EFO_0000305","breast carcinoma","CHEMBL1201182","TEMSIROLIMUS","FK506-binding protein 1A inhibitor","INHIBITOR","ENSG00000088832","FKBP prolyl isomerase 1A","FKBP1A","Small molecule","NCT00376688"
"231",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04265274","MONDO_0007254","breast cancer","CHEMBL964","DISULFIRAM","Aldehyde dehydrogenase inhibitor","INHIBITOR","ENSG00000111275","aldehyde dehydrogenase 2 family member","ALDH2","Small molecule","NCT04265274"
"232",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01792050","MONDO_0007254","breast cancer","CHEMBL571209","INDOXIMOD","mTORC1 activator","ACTIVATOR","ENSG00000198793","mechanistic target of rapamycin kinase","MTOR","Small molecule","NCT01792050"
"233",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04603911","MONDO_0007254","breast cancer","CHEMBL134","CLONIDINE","Adrenergic receptor alpha-2 agonist","AGONIST","ENSG00000150594","adrenoceptor alpha 2A","ADRA2A","Small molecule","NCT04603911"
"234",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03383679","MONDO_0007254","breast cancer","CHEMBL4297185","DAROLUTAMIDE","Androgen Receptor antagonist","ANTAGONIST","ENSG00000169083","androgen receptor","AR","Small molecule","NCT03383679"
"235",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00070031","MONDO_0007254","breast cancer","CHEMBL435191","EDOTECARIN","DNA topoisomerase I inhibitor","INHIBITOR","ENSG00000198900","DNA topoisomerase I","TOP1","Small molecule","NCT00070031"
"236",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04676516","MONDO_0007254","breast cancer","CHEMBL4466233","PEMRAMETOSTAT","Protein arginine N-methyltransferase 5 inhibitor","INHIBITOR","ENSG00000100462","protein arginine methyltransferase 5","PRMT5","Small molecule","NCT04676516"
"237",2,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00080756","Orphanet_145","Hereditary breast and ovarian cancer syndrome","CHEMBL386630","TESTOSTERONE","Androgen Receptor agonist","AGONIST","ENSG00000169083","androgen receptor","AR","Small molecule","NCT00080756"
"238",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00081510","MONDO_0007254","breast cancer","CHEMBL298734","LONAFARNIB","Protein farnesyltransferase inhibitor","INHIBITOR","ENSG00000168522","farnesyltransferase, CAAX box, beta","FNTB","Small molecule","NCT00081510"
"239",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01299038","MONDO_0007254","breast cancer","CHEMBL1496","ROSUVASTATIN","HMG-CoA reductase inhibitor","INHIBITOR","ENSG00000113161","3-hydroxy-3-methylglutaryl-CoA reductase","HMGCR","Small molecule","NCT01299038"
"240",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03971409","EFO_0005537","triple-negative breast cancer","CHEMBL3187723","BINIMETINIB","Dual specificity mitogen-activated protein kinase kinase 2 inhibitor","INHIBITOR","ENSG00000126934","mitogen-activated protein kinase kinase 2","MAP2K2","Small molecule","NCT03971409"
"241",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00004906","MONDO_0007254","breast cancer","CHEMBL3989401","PAMIDRONATE DISODIUM","Farnesyl diphosphate synthase inhibitor","INHIBITOR","ENSG00000160752","farnesyl diphosphate synthase","FDPS","Small molecule","NCT00004906"
"242",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01105650","MONDO_0007254","breast cancer","CHEMBL650","METHYLPREDNISOLONE","Glucocorticoid receptor agonist","AGONIST","ENSG00000113580","nuclear receptor subfamily 3 group C member 1","NR3C1","Small molecule","NCT01105650"
"243",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02142959","MONDO_0007254","breast cancer","CHEMBL4303525","OMAVELOXOLONE","Nuclear factor erythroid 2-related factor 2 activator","ACTIVATOR","ENSG00000116044","NFE2 like bZIP transcription factor 2","NFE2L2","Small molecule","NCT02142959"
"244",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00003752","MONDO_0007254","breast cancer","CHEMBL1023","BEXAROTENE","Retinoid X receptor agonist","AGONIST","ENSG00000204231","retinoid X receptor beta","RXRB","Small molecule","NCT00003752"
"245",2,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03624543","MONDO_0007254","breast cancer","CHEMBL4297462","CFI-400945","Serine/threonine-protein kinase PLK4 inhibitor","INHIBITOR","ENSG00000142731","polo like kinase 4","PLK4","Small molecule","NCT03624543"
"246",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00451555","MONDO_0007254","breast cancer","CHEMBL300138","ENZASTAURIN","Protein kinase C beta inhibitor","INHIBITOR","ENSG00000166501","protein kinase C beta","PRKCB","Small molecule","NCT00451555"
"247",2,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02299999","MONDO_0007254","breast cancer","CHEMBL2336325","VISTUSERTIB","Serine/threonine-protein kinase mTOR inhibitor","INHIBITOR","ENSG00000198793","mechanistic target of rapamycin kinase","MTOR","Small molecule","NCT02299999"
"248",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00733408","EFO_0005537","triple-negative breast cancer","CHEMBL1079742","ERLOTINIB HYDROCHLORIDE","Epidermal growth factor receptor erbB1 inhibitor","INHIBITOR","ENSG00000146648","epidermal growth factor receptor","EGFR","Small molecule","NCT00733408"
"249",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00577122","MONDO_0007254","breast cancer","CHEMBL103","PROGESTERONE","Progesterone receptor agonist","AGONIST","ENSG00000082175","progesterone receptor","PGR","Small molecule","NCT00577122"
"250",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02988986","MONDO_0007254","breast cancer","CHEMBL3545097","SAPANISERTIB","Serine/threonine-protein kinase mTOR inhibitor","INHIBITOR","ENSG00000198793","mechanistic target of rapamycin kinase","MTOR","Small molecule","NCT02988986"
"251",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03768492","EFO_0000305","breast carcinoma","CHEMBL113","CAFFEINE","Adenosine receptor antagonist","ANTAGONIST","ENSG00000163485","adenosine A3 receptor","ADORA3","Small molecule","NCT03768492"
"252",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05025735","MONDO_0007254","breast cancer","CHEMBL429910","DAPAGLIFLOZIN","Sodium/glucose cotransporter 2 inhibitor","INHIBITOR","ENSG00000140675","solute carrier family 5 member 2","SLC5A2","Small molecule","NCT05025735"
"253",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04588935","MONDO_0007254","breast cancer","CHEMBL1581","PERINDOPRIL","Angiotensin-converting enzyme inhibitor","INHIBITOR","ENSG00000159640","angiotensin I converting enzyme","ACE","Small molecule","NCT04588935"
"254",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00416403","MONDO_0007254","breast cancer","CHEMBL2220442","FLUVASTATIN","HMG-CoA reductase inhibitor","INHIBITOR","ENSG00000113161","3-hydroxy-3-methylglutaryl-CoA reductase","HMGCR","Small molecule","NCT00416403"
"255",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03094052","EFO_0000304","breast adenocarcinoma","CHEMBL1201294","DIPHENOXYLATE","Mu opioid receptor agonist","AGONIST","ENSG00000112038","opioid receptor mu 1","OPRM1","Small molecule","NCT03094052"
"256",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02408770","MONDO_0007254","breast cancer","CHEMBL260538","ULIPRISTAL ACETATE","Progesterone receptor modulator","MODULATOR","ENSG00000082175","progesterone receptor","PGR","Small molecule","NCT02408770"
"257",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02400476","MONDO_0007254","breast cancer","CHEMBL1370","BUDESONIDE","Glucocorticoid receptor agonist","AGONIST","ENSG00000113580","nuclear receptor subfamily 3 group C member 1","NR3C1","Small molecule","NCT02400476"
"258",2,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02299999","MONDO_0007254","breast cancer","CHEMBL2408045","SAPITINIB","Receptor tyrosine-protein kinase erbB-3 inhibitor","INHIBITOR","ENSG00000065361","erb-b2 receptor tyrosine kinase 3","ERBB3","Small molecule","NCT02299999"
"259",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04355858","MONDO_0007254","breast cancer","CHEMBL4650276","SHR3680","Androgen Receptor antagonist","ANTAGONIST","ENSG00000169083","androgen receptor","AR","Small molecule","NCT04355858"
"260",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00499122","MONDO_0007254","breast cancer","CHEMBL1372","OXIGLUTATIONE","Glutathione reductase","OTHER","ENSG00000104687","glutathione-disulfide reductase","GSR","Small molecule","NCT00499122"
"261",2,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04862585","MONDO_0004658","breast carcinoma in situ","CHEMBL30","CIMETIDINE","Histamine H2 receptor antagonist","ANTAGONIST","ENSG00000113749","histamine receptor H2","HRH2","Small molecule","NCT04862585"
"262",2,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02957968","EFO_0000304","breast adenocarcinoma","CHEMBL1201129","DECITABINE","DNA (cytosine-5)-methyltransferase 3A inhibitor","INHIBITOR","ENSG00000130816","DNA methyltransferase 3 alpha","DNMT3A","Small molecule","NCT02957968"
"263",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00004046","MONDO_0007254","breast cancer","CHEMBL1614650","EXATECAN","DNA topoisomerase I inhibitor","INHIBITOR","ENSG00000198900","DNA topoisomerase I","TOP1","Small molecule","NCT00004046"
"264",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00951054","MONDO_0007254","breast cancer","CHEMBL837","7-ETHYL-10-HYDROXYCAMPTOTHECIN","DNA topoisomerase I inhibitor","INHIBITOR","ENSG00000198900","DNA topoisomerase I","TOP1","Small molecule","NCT00951054"
"265",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01416389","MONDO_0007254","breast cancer","CHEMBL2105661","LITRONESIB","Kinesin-like protein 1 inhibitor","INHIBITOR","ENSG00000138160","kinesin family member 11","KIF11","Small molecule","NCT01416389"
"266",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01712009","MONDO_0007254","breast cancer","CHEMBL154","NAPROXEN","Cyclooxygenase inhibitor","INHIBITOR","ENSG00000073756","prostaglandin-endoperoxide synthase 2","PTGS2","Small molecule","NCT01712009"
"267",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03084536","MONDO_0007254","breast cancer","CHEMBL596","FENTANYL","Mu opioid receptor agonist","AGONIST","ENSG00000112038","opioid receptor mu 1","OPRM1","Small molecule","NCT03084536"
"268",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00200174","MONDO_0007254","breast cancer","CHEMBL1116","RALOXIFENE HYDROCHLORIDE","Estrogen receptor beta modulator","MODULATOR","ENSG00000140009","estrogen receptor 2","ESR2","Small molecule","NCT00200174"
"269",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00005873","MONDO_0007254","breast cancer","CHEMBL77305","RUBITECAN","DNA topoisomerase I inhibitor","INHIBITOR","ENSG00000198900","DNA topoisomerase I","TOP1","Small molecule","NCT00005873"
"270",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01293682","MONDO_0007254","breast cancer","CHEMBL846","CALCITRIOL","Vitamin D receptor agonist","AGONIST","ENSG00000111424","vitamin D receptor","VDR","Small molecule","NCT01293682"
"271",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01575522","EFO_0005537","triple-negative breast cancer","CHEMBL2103882","TIVANTINIB","Hepatocyte growth factor receptor inhibitor","INHIBITOR","ENSG00000105976","MET proto-oncogene, receptor tyrosine kinase","MET","Small molecule","NCT01575522"
"272",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01712009","MONDO_0007254","breast cancer","CHEMBL998","LORATADINE","Histamine H1 receptor antagonist","ANTAGONIST","ENSG00000196639","histamine receptor H1","HRH1","Small molecule","NCT01712009"
"273",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01785992","MONDO_0007254","breast cancer","CHEMBL286738","IROSUSTAT","Steryl-sulfatase inhibitor","INHIBITOR","ENSG00000101846","steroid sulfatase","STS","Small molecule","NCT01785992"
"274",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03057600","EFO_0005537","triple-negative breast cancer","CHEMBL3639788","TELAGLENASTAT","Glutaminase kidney isoform, mitochondrial inhibitor","INHIBITOR","ENSG00000115419","glutaminase","GLS","Small molecule","NCT03057600"
"275",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00899574","MONDO_0007254","breast cancer","CHEMBL1282","IMIQUIMOD","Toll-like receptor 7 agonist","AGONIST","ENSG00000196664","toll like receptor 7","TLR7","Small molecule","NCT00899574"
"276",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02839668","MONDO_0007254","breast cancer","CHEMBL1237044","TRAMADOL","Mu opioid receptor agonist","AGONIST","ENSG00000112038","opioid receptor mu 1","OPRM1","Small molecule","NCT02839668"
"277",2,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05021900","MONDO_0007254","breast cancer","CHEMBL4297584","TENALISIB","PI3-kinase p110-gamma subunit inhibitor","INHIBITOR","ENSG00000105851","phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma","PIK3CG","Small molecule","NCT05021900"
"278",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01082068","MONDO_0007254","breast cancer","CHEMBL3545366","VOXTALISIB","PI3-kinase class I inhibitor","INHIBITOR","ENSG00000145675","phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta","PIK3CB","Small molecule","NCT01082068"
"279",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00717340","MONDO_0007254","breast cancer","CHEMBL1289494","TIVOZANIB","Vascular endothelial growth factor receptor inhibitor","INHIBITOR","ENSG00000102755","fms related receptor tyrosine kinase 1","FLT1","Small molecule","NCT00717340"
"280",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02259114","MONDO_0007254","breast cancer","CHEMBL3581647","BIRABRESIB","Bromodomain and extra-terminal motif (BET) inhibitor","INHIBITOR","ENSG00000204256","bromodomain containing 4","BRD4","Small molecule","NCT02259114"
"281",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00001444","MONDO_0007254","breast cancer","CHEMBL574737","UCN-01","Cyclin-dependent kinase 6 inhibitor","INHIBITOR","ENSG00000140992","cyclin dependent kinase 6","CDK6","Small molecule","NCT00001444"
"282",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02632071","EFO_0000305","breast carcinoma","CHEMBL2364628","RICOLINOSTAT","Histone deacetylase 6 inhibitor","INHIBITOR","ENSG00000094631","histone deacetylase 6","HDAC6","Small molecule","NCT02632071"
"283",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01624441","EFO_0006861","male breast carcinoma","CHEMBL2103840","DINACICLIB","Cyclin-dependent kinase 5 inhibitor","INHIBITOR","ENSG00000136807","cyclin dependent kinase 5","CDK5","Small molecule","NCT01624441"
"284",1,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03854903","EFO_0000305","breast carcinoma","CHEMBL288441","BOSUTINIB","Tyrosine-protein kinase ABL inhibitor","INHIBITOR","ENSG00000197122","ABL proto-oncogene 1, non-receptor tyrosine kinase","ABL1","Small molecule","NCT03854903"
"285",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00637897","MONDO_0007254","breast cancer","CHEMBL1200622","PARICALCITOL","Vitamin D receptor agonist","AGONIST","ENSG00000111424","vitamin D receptor","VDR","Small molecule","NCT00637897"
"286",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00001504","MONDO_0007254","breast cancer","CHEMBL705","ALITRETINOIN","Retinoid receptor agonist","AGONIST","ENSG00000204231","retinoic acid receptor alpha","RARA","Small molecule","NCT00001504"
"287",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02705859","MONDO_0007254","breast cancer","CHEMBL3218576","COPANLISIB","PI3-kinase p110-alpha subunit inhibitor","INHIBITOR","ENSG00000171608","phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha","PIK3CA","Small molecule","NCT02705859"
"288",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00600275","MONDO_0007254","breast cancer","CHEMBL3545096","BGT-226","PI3-kinase class I inhibitor","INHIBITOR","ENSG00000145675","phosphoinositide-3-kinase regulatory subunit 5","PIK3R5","Small molecule","NCT00600275"
"289",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04483505","MONDO_0007254","breast cancer","CHEMBL3963485","ROGARATINIB","Fibroblast growth factor receptor inhibitor","INHIBITOR","ENSG00000068078","fibroblast growth factor receptor 2","FGFR2","Small molecule","NCT04483505"
"290",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00020332","MONDO_0007254","breast cancer","CHEMBL428690","ALVOCIDIB","Cyclin-dependent kinase 9 inhibitor","INHIBITOR","ENSG00000136807","cyclin dependent kinase 9","CDK9","Small molecule","NCT00020332"
"291",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00773344","MONDO_0007254","breast cancer","CHEMBL109480","TANESPIMYCIN","Heat shock protein HSP90 inhibitor","INHIBITOR","ENSG00000080824","heat shock protein 90 alpha family class A member 1","HSP90AA1","Small molecule","NCT00773344"
"292",1,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05608252","MONDO_0007254","breast cancer","CHEMBL3264002","AVUTOMETINIB","Dual specificity mitogen-activated protein kinase kinase 1 inhibitor","INHIBITOR","ENSG00000126934","mitogen-activated protein kinase kinase 1","MAP2K1","Small molecule","NCT05608252"
"293",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03941743","EFO_0000305","breast carcinoma","CHEMBL544665","FINGOLIMOD HYDROCHLORIDE","Sphingosine 1-phosphate receptor agonist","AGONIST","ENSG00000180739","sphingosine-1-phosphate receptor 4","S1PR4","Small molecule","NCT03941743"
"294",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01042925","MONDO_0007254","breast cancer","CHEMBL3360203","PILARALISIB","PI3-kinase class I inhibitor","INHIBITOR","ENSG00000145675","phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha","PIK3CA","Small molecule","NCT01042925"
"295",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00337649","MONDO_0007254","breast cancer","CHEMBL96172","EPOTHILONE D","Tubulin stabiliser","STABILISER","ENSG00000188229","tubulin beta 8 class VIII","TUBB8","Small molecule","NCT00337649"
"296",1,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05340673","EFO_0000432","breast ductal carcinoma in situ","CHEMBL306823","SODIUM DICHLOROACETATE","Pyruvate dehydrogenase kinase inhibitor","INHIBITOR","ENSG00000005882","pyruvate dehydrogenase kinase 3","PDK3","Small molecule","NCT05340673"
"297",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02027376","MONDO_0007254","breast cancer","CHEMBL2105737","SONIDEGIB","Smoothened homolog inhibitor","INHIBITOR","ENSG00000128602","smoothened, frizzled class receptor","SMO","Small molecule","NCT02027376"
"298",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00005822","MONDO_0007254","breast cancer","CHEMBL276711","SEMAXANIB","Vascular endothelial growth factor receptor inhibitor","INHIBITOR","ENSG00000102755","fms related receptor tyrosine kinase 4","FLT4","Small molecule","NCT00005822"
"299",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02646748","MONDO_0007254","breast cancer","CHEMBL3622820","ITACITINIB","Tyrosine-protein kinase JAK1 inhibitor","INHIBITOR","ENSG00000162434","Janus kinase 1","JAK1","Small molecule","NCT02646748"
"300",1,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04205903","MONDO_0007254","breast cancer","CHEMBL255863","NILOTINIB","Bcr/Abl fusion protein","INHIBITOR","ENSG00000097007","BCR activator of RhoGEF and GTPase","BCR","Small molecule","NCT04205903"
"301",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01246102","MONDO_0007254","breast cancer","CHEMBL1214827","ONALESPIB","Heat shock protein HSP90 inhibitor","INHIBITOR","ENSG00000080824","heat shock protein 90 alpha family class A member 1","HSP90AA1","Small molecule","NCT01246102"
"302",1,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05383196","EFO_1000984","inflammatory breast carcinoma","CHEMBL1738758","ONVANSERTIB","Serine/threonine-protein kinase PLK1 inhibitor","INHIBITOR","ENSG00000166851","polo like kinase 1","PLK1","Small molecule","NCT05383196"
"303",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01171924","MONDO_0007254","breast cancer","CHEMBL598797","CUDC-101","Histone deacetylase inhibitor","INHIBITOR","ENSG00000146648","histone deacetylase 7","HDAC7","Small molecule","NCT01171924"
"304",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03505528","MONDO_0007254","breast cancer","CHEMBL1200895","PHENELZINE SULFATE","Monoamine oxidase inhibitor","INHIBITOR","ENSG00000189221","monoamine oxidase A","MAOA","Small molecule","NCT03505528"
"305",1,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03218826","EFO_0005537","triple-negative breast cancer","CHEMBL3408248","AZD-8186","PI3-kinase p110-beta subunit inhibitor","INHIBITOR","ENSG00000171608","phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta","PIK3CB","Small molecule","NCT03218826"
"306",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00001944","MONDO_0007254","breast cancer","CHEMBL348475","TARIQUIDAR","P-glycoprotein 1 inhibitor","INHIBITOR","ENSG00000085563","ATP binding cassette subfamily B member 1","ABCB1","Small molecule","NCT00001944"
"307",1,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04851613","MONDO_0007254","breast cancer","CHEMBL2219422","AFURESERTIB","Serine/threonine-protein kinase AKT inhibitor","INHIBITOR","ENSG00000105221","AKT serine/threonine kinase 2","AKT2","Small molecule","NCT04851613"
"308",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01271920","MONDO_0007254","breast cancer","CHEMBL252164","LUMINESPIB","Heat shock protein HSP90 inhibitor","INHIBITOR","ENSG00000080824","heat shock protein 90 alpha family class A member 1","HSP90AA1","Small molecule","NCT01271920"
"309",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01248494","MONDO_0007254","breast cancer","CHEMBL1879463","DACTOLISIB","PI3-kinase class I inhibitor","INHIBITOR","ENSG00000145675","phosphoinositide-3-kinase regulatory subunit 1","PIK3R1","Small molecule","NCT01248494"
"310",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00322400","MONDO_0007254","breast cancer","CHEMBL572881","MOTESANIB","Platelet-derived growth factor receptor inhibitor","INHIBITOR","ENSG00000165731","platelet derived growth factor receptor beta","PDGFRB","Small molecule","NCT00322400"
"311",1,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05092373","EFO_0000305","breast carcinoma","CHEMBL2103868","CABOZANTINIB S-MALATE","Hepatocyte growth factor receptor inhibitor","INHIBITOR","ENSG00000128052","MET proto-oncogene, receptor tyrosine kinase","MET","Small molecule","NCT05092373"
"312",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00054028","MONDO_0007254","breast cancer","CHEMBL265502","SURAMIN","Acidic fibroblast growth factor inhibitor","INHIBITOR","ENSG00000113578","fibroblast growth factor 1","FGF1","Small molecule","NCT00054028"
"313",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03505528","MONDO_0007254","breast cancer","CHEMBL1089","PHENELZINE","Monoamine oxidase inhibitor","INHIBITOR","ENSG00000189221","monoamine oxidase A","MAOA","Small molecule","NCT03505528"
"314",1,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03709446","MONDO_0007254","breast cancer","CHEMBL960","LEFLUNOMIDE","Dihydroorotate dehydrogenase inhibitor","INHIBITOR","ENSG00000102967","dihydroorotate dehydrogenase (quinone)","DHODH","Small molecule","NCT03709446"
"315",1,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03012230","EFO_0005537","triple-negative breast cancer","CHEMBL1795071","RUXOLITINIB PHOSPHATE","Tyrosine-protein kinase JAK2 inhibitor","INHIBITOR","ENSG00000096968","Janus kinase 2","JAK2","Small molecule","NCT03012230"
"316",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03344536","MONDO_0007254","breast cancer","CHEMBL3907479","FGFR INHIBITOR DEBIO 1347","Fibroblast growth factor receptor 2 inhibitor","INHIBITOR","ENSG00000068078","fibroblast growth factor receptor 2","FGFR2","Small molecule","NCT03344536"
"317",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00268918","MONDO_0007254","breast cancer","CHEMBL101253","VATALANIB","Macrophage colony stimulating factor receptor inhibitor","INHIBITOR","ENSG00000113721","colony stimulating factor 1 receptor","CSF1R","Small molecule","NCT00268918"
"318",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04261218","MONDO_0007254","breast cancer","CHEMBL4073443","TOMIVOSERTIB","MAP kinase-interacting serine/threonine-protein kinase 1/2 inhibitor","INHIBITOR","ENSG00000099875","MAPK interacting serine/threonine kinase 1","MKNK1","Small molecule","NCT04261218"
"319",1,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04345913","EFO_0005537","triple-negative breast cancer","CHEMBL3545068","COPANLISIB HYDROCHLORIDE","PI3-kinase p110-alpha subunit inhibitor","INHIBITOR","ENSG00000121879","phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha","PIK3CA","Small molecule","NCT04345913"
"320",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02834403","MONDO_0007254","breast cancer","CHEMBL256147","TILARGININE","Nitric oxide synthase inhibitor","INHIBITOR","ENSG00000089250","nitric oxide synthase 1","NOS1","Small molecule","NCT02834403"
"321",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02834403","MONDO_0007254","breast cancer","CHEMBL25","ASPIRIN","Cyclooxygenase inhibitor","INHIBITOR","ENSG00000073756","prostaglandin-endoperoxide synthase 1","PTGS1","Small molecule","NCT02834403"
"322",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00788333","MONDO_0007254","breast cancer","CHEMBL575448","BMS-754807","Insulin-like growth factor I receptor inhibitor","INHIBITOR","ENSG00000140443","insulin like growth factor 1 receptor","IGF1R","Small molecule","NCT00788333"
"323",1,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03379428","MONDO_0007254","breast cancer","CHEMBL1873475","IBRUTINIB","Tyrosine-protein kinase BTK inhibitor","INHIBITOR","ENSG00000010671","Bruton tyrosine kinase","BTK","Small molecule","NCT03379428"
"324",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03346161","MONDO_0007254","breast cancer","CHEMBL3","NICOTINE","Neuronal acetylcholine receptor; alpha4/beta2 agonist","AGONIST","ENSG00000160716","cholinergic receptor nicotinic alpha 4 subunit","CHRNA4","Small molecule","NCT03346161"
"325",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00055926","MONDO_0007254","breast cancer","CHEMBL483321","CP-724714","Receptor protein-tyrosine kinase erbB-2 inhibitor","INHIBITOR","ENSG00000141736","erb-b2 receptor tyrosine kinase 2","ERBB2","Small molecule","NCT00055926"
"326",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03941743","EFO_0000305","breast carcinoma","CHEMBL314854","FINGOLIMOD","Sphingosine 1-phosphate receptor binding agent","BINDING AGENT","ENSG00000180739","sphingosine-1-phosphate receptor 5","S1PR5","Small molecule","NCT03941743"
"327",1,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05673200","EFO_0005537","triple-negative breast cancer","CHEMBL3237547","CEDAZURIDINE","Cytidine deaminase inhibitor","INHIBITOR","ENSG00000158825","cytidine deaminase","CDA","Small molecule","NCT05673200"
"328",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00508586","MONDO_0007254","breast cancer","CHEMBL4650336","EMVODODSTAT","Dihydroorotate dehydrogenase inhibitor","INHIBITOR","ENSG00000102967","dihydroorotate dehydrogenase (quinone)","DHODH","Small molecule","NCT00508586"
"329",1,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05618613","MONDO_0007254","breast cancer","CHEMBL1908373","ONAPRISTONE","Progesterone receptor antagonist","ANTAGONIST","ENSG00000082175","progesterone receptor","PGR","Small molecule","NCT05618613"
"330",1,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04205903","MONDO_0007254","breast cancer","CHEMBL1201740","NILOTINIB HYDROCHLORIDE MONOHYDRATE","Tyrosine-protein kinase ABL inhibitor","INHIBITOR","ENSG00000097007","ABL proto-oncogene 1, non-receptor tyrosine kinase","ABL1","Small molecule","NCT04205903"
"331",1,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04052555","EFO_0005537","triple-negative breast cancer","CHEMBL3989870","BERZOSERTIB","Serine-protein kinase ATR inhibitor","INHIBITOR","ENSG00000175054","ATR serine/threonine kinase","ATR","Small molecule","NCT04052555"
"332",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02580448","EFO_0006861","male breast carcinoma","CHEMBL3264610","SEVITERONEL","Androgen Receptor antagonist","ANTAGONIST","ENSG00000169083","androgen receptor","AR","Small molecule","NCT02580448"
"333",1,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02419495","EFO_0005537","triple-negative breast cancer","CHEMBL1607","TOPOTECAN HYDROCHLORIDE","DNA topoisomerase I, mitochondrial inhibitor","INHIBITOR","ENSG00000184428","DNA topoisomerase I mitochondrial","TOP1MT","Small molecule","NCT02419495"
"334",1,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02791334","MONDO_0007254","breast cancer","CHEMBL3545307","MERESTINIB","Hepatocyte growth factor receptor inhibitor","INHIBITOR","ENSG00000105976","MET proto-oncogene, receptor tyrosine kinase","MET","Small molecule","NCT02791334"
"335",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02834403","MONDO_0007254","breast cancer","CHEMBL1491","AMLODIPINE","Voltage-gated L-type calcium channel blocker","BLOCKER","ENSG00000151067","calcium voltage-gated channel subunit alpha1 D","CACNA1D","Small molecule","NCT02834403"
"336",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01390818","MONDO_0007254","breast cancer","CHEMBL2107832","PIMASERTIB","Dual specificity mitogen-activated protein kinase kinase 2 inhibitor","INHIBITOR","ENSG00000169032","mitogen-activated protein kinase kinase 2","MAP2K2","Small molecule","NCT01390818"
"337",1,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04520269","MONDO_0007254","breast cancer","CHEMBL2035187","PACRITINIB","Tyrosine-protein kinase JAK2 inhibitor","INHIBITOR","ENSG00000122025","Janus kinase 2","JAK2","Small molecule","NCT04520269"
"338",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00803556","MONDO_0007254","breast cancer","CHEMBL383824","ALVESPIMYCIN","Heat shock protein HSP90 inhibitor","INHIBITOR","ENSG00000080824","heat shock protein 90 alpha family class A member 1","HSP90AA1","Small molecule","NCT00803556"
"339",1,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02672475","EFO_0005537","triple-negative breast cancer","CHEMBL2364611","GALUNISERTIB","TGF-beta receptor type I inhibitor","INHIBITOR","ENSG00000106799","transforming growth factor beta receptor 1","TGFBR1","Small molecule","NCT02672475"
"340",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02646748","MONDO_0007254","breast cancer","CHEMBL4297615","PARSACLISIB","PI3-kinase p110-delta subunit inhibitor","INHIBITOR","ENSG00000171608","phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta","PIK3CD","Small molecule","NCT02646748"
"341",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01177397","MONDO_0007254","breast cancer","CHEMBL3586404","ONATASERTIB","Serine/threonine-protein kinase mTOR inhibitor","INHIBITOR","ENSG00000198793","mechanistic target of rapamycin kinase","MTOR","Small molecule","NCT01177397"
"342",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02621957","MONDO_0007254","breast cancer","CHEMBL3581693","BRILANESTRANT","Estrogen receptor alpha antagonist","ANTAGONIST","ENSG00000091831","estrogen receptor 1","ESR1","Small molecule","NCT02621957"
"343",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00933309","MONDO_0007254","breast cancer","CHEMBL121","ROSIGLITAZONE","Peroxisome proliferator-activated receptor gamma agonist","AGONIST","ENSG00000132170","peroxisome proliferator activated receptor gamma","PPARG","Small molecule","NCT00933309"
"344",1,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05243641","MONDO_0007254","breast cancer","CHEMBL3188267","CAPMATINIB","Hepatocyte growth factor receptor inhibitor","INHIBITOR","ENSG00000105976","MET proto-oncogene, receptor tyrosine kinase","MET","Small molecule","NCT05243641"
"345",1,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04481113","EFO_0000304","breast adenocarcinoma","CHEMBL3989922","NIRAPARIB TOSYLATE","Poly [ADP-ribose] polymerase-1 inhibitor","INHIBITOR","ENSG00000143799","poly(ADP-ribose) polymerase 1","PARP1","Small molecule","NCT04481113"
"346",1,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03387085","MONDO_0007254","breast cancer","CHEMBL2107818","ALDOXORUBICIN","DNA topoisomerase II alpha inhibitor","INHIBITOR","ENSG00000131747","DNA topoisomerase II alpha","TOP2A","Small molecule","NCT03387085"
"347",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03507543","MONDO_0007254","breast cancer","CHEMBL4802152","SENAPARIB","Poly [ADP-ribose] polymerase 2 inhibitor","INHIBITOR","ENSG00000129484","poly(ADP-ribose) polymerase 2","PARP2","Small molecule","NCT03507543"
"348",1,"Recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04577963","MONDO_0007254","breast cancer","CHEMBL4303214","FRUQUINTINIB","Vascular endothelial growth factor receptor inhibitor","INHIBITOR","ENSG00000102755","fms related receptor tyrosine kinase 4","FLT4","Small molecule","NCT04577963"
"349",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01033032","MONDO_0007254","breast cancer","CHEMBL1186894","AMRUBICIN","DNA topoisomerase II alpha inhibitor","INHIBITOR","ENSG00000131747","DNA topoisomerase II alpha","TOP2A","Small molecule","NCT01033032"
"350",1,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02419495","EFO_0005537","triple-negative breast cancer","CHEMBL84","TOPOTECAN","DNA topoisomerase I, mitochondrial inhibitor","INHIBITOR","ENSG00000184428","DNA topoisomerase I mitochondrial","TOP1MT","Small molecule","NCT02419495"
"351",1,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03238196","MONDO_0007254","breast cancer","CHEMBL3545376","ERDAFITINIB","Fibroblast growth factor receptor inhibitor","INHIBITOR","ENSG00000068078","fibroblast growth factor receptor 4","FGFR4","Small molecule","NCT03238196"
"352",1,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02950259","MONDO_0007254","breast cancer","CHEMBL6","INDOMETHACIN","Cyclooxygenase inhibitor","INHIBITOR","ENSG00000073756","prostaglandin-endoperoxide synthase 1","PTGS1","Small molecule","NCT02950259"
"353",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT00003038","MONDO_0007254","breast cancer","CHEMBL413376","SURAMIN HEXASODIUM","Acidic fibroblast growth factor inhibitor","INHIBITOR","ENSG00000113578","fibroblast growth factor 1","FGF1","Small molecule","NCT00003038"
"354",1,"Active, not recruiting","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT05041101","EFO_0000305","breast carcinoma","CHEMBL3039498","GRAPIPRANT","Prostanoid EP4 receptor antagonist","ANTAGONIST","ENSG00000171522","prostaglandin E receptor 4","PTGER4","Small molecule","NCT05041101"
"355",1,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT04103853","MONDO_0007254","breast cancer","CHEMBL4594417","GT-0918","Androgen Receptor antagonist","ANTAGONIST","ENSG00000169083","androgen receptor","AR","Small molecule","NCT04103853"
"356",0.5,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT03122444","MONDO_0007254","breast cancer","CHEMBL11","IMIPRAMINE","Serotonin transporter inhibitor","INHIBITOR","ENSG00000103546","solute carrier family 6 member 4","SLC6A4","Small molecule","NCT03122444"
"357",0.5,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02806817","EFO_0000305","breast carcinoma","CHEMBL3545320","ME-344","Mitochondrial complex I (NADH dehydrogenase) inhibitor","INHIBITOR","ENSG00000198695","NADH:ubiquinone oxidoreductase subunit A10","NDUFA10","Small molecule","NCT02806817"
"358",0.5,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01380353","MONDO_0007254","breast cancer","CHEMBL139","DICLOFENAC","Cyclooxygenase inhibitor","INHIBITOR","ENSG00000073756","prostaglandin-endoperoxide synthase 1","PTGS1","Small molecule","NCT01380353"
"359",0.5,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02352025","MONDO_0007254","breast cancer","CHEMBL198877","AUS-131","Estrogen receptor beta agonist","AGONIST","ENSG00000140009","estrogen receptor 2","ESR2","Small molecule","NCT02352025"
"360",0.5,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01380353","MONDO_0007254","breast cancer","CHEMBL1201180","DICLOFENAC EPOLAMINE","Cyclooxygenase inhibitor","INHIBITOR","ENSG00000073756","prostaglandin-endoperoxide synthase 2","PTGS2","Small molecule","NCT01380353"
"361",0.5,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT01730729","MONDO_0007254","breast cancer","CHEMBL1201087","CABERGOLINE","Dopamine D2 receptor agonist","AGONIST","ENSG00000149295","dopamine receptor D2","DRD2","Small molecule","NCT01730729"
"362",0.5,"Completed","ClinicalTrials","https://clinicaltrials.gov/ct2/show/NCT02463383","MONDO_0007254","breast cancer","CHEMBL521","IBUPROFEN","Cyclooxygenase inhibitor","INHIBITOR","ENSG00000073756","prostaglandin-endoperoxide synthase 2","PTGS2","Small molecule","NCT02463383"
